Valeant Receives FDA Approval Of SILIQ Brodalumab For ModerateToSevere Plaque Psoriasis

LAVAL Quebec Feb. 16 2017 PRNewswire Valeant Pharmaceuticals International Inc. NYSE & TSX VRX today announced that the U.S. Food and Drug Administration FDA has approved the Biologics License Application BLA for SILIQ brodalumab injection for sub...